# Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury

> **NCT01802996** · PHASE4 · UNKNOWN · sponsor: **Cttq** · enrollment: 2040 (estimated)

## Conditions studied

- Neoplasms
- Liver Injury

## Interventions

- **DRUG:** Magnesium Isoglycyrrhizinate Injection

## Key facts

- **NCT ID:** NCT01802996
- **Lead sponsor:** Cttq
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-03
- **Primary completion:** 2014-08
- **Final completion:** 2014-08
- **Target enrollment:** 2040 (ESTIMATED)
- **Last updated:** 2013-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01802996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01802996, "Evaluate the Efficacy of Magnesium Isoglycyrrhizinate in the Prevention of Chemotherapy Related Acute Liver Injury". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01802996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*